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Abstract 
The pathogenesis of aspirin-induced asthma (AIA) is presumed to involve the aspirin 
/non-steroidal anti-inflammatory drug (NSAID)-induced abnormal metabolism of 
arachidonic acid, resulting in an increase in 5-lopoxygenase (5-LO) metabolites, 
particularly leukotriene C4 (LTC4) which is a highly potent bronchial constrictor. 
However, the role of LTC4 in the development of AIA has yet to be conclusively 
demonstrated. To elucidate the effect of LTC4 on the development of AIA, we generated 
LTC4 synthase (Ltc4s) gene transgenic (LTC4S-Tg) mice. In contrast to wild-type (WT) 
mice, LTC4S-Tg mice displayed NSAID-induced airway obstruction that was associated 
with increases of LTC4 and Th2 cytokines in lung tissue. This is the first study to 
demonstrate clearly that a balance shift towards the 5-LO pathway contributes to the 
pathogenesis of AIA in the presence of elevated levels of LTC4S. 
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The arachidonic acid (AA) cascade is divided into two major pathways: the 
cyclooxygenase (COX) pathway, which yields prostanoids (prostagrandins (PGs) and 
thromboxane A2), and the lipoxygenase (LO) pathway, which produces leukotrienes 
(LTs). The sequential catalytic action of 5-lipoxygenase (LO), which is only expressed 
in eosinophils, basophils, mast cells, macrophages, platelets, and endothelial cells, on 
AA generates LTA4, which is either hydroxylated to LTB4 or metabolized into the first 
of the cysteinyl (cys) LTs, LTC4, by the action of LTC4 synthase (LTC4S)1-5. LTC4 is 
further converted to LTD4 in the extracellular space, which is in turn cleaved to form 
LTE46. It is known that cys-LTs play important roles in the pathogenesis of asthma, such 
as airway remodeling that is characterized by contraction and hyperplasia of bronchial 
smooth muscle, enhancement of secretion from the bronchial gland, increased vascular 
permeability, and the recruitment of eosinophils7-10. 
Recently, the relevance of cys-LTs in the development of aspirin-induced asthma 
(AIA) has emerged from clinical studies11,12. AIA affects 5-10% of adults with chronic 
asthma, in whom acute bronchoconstriction is induced by the ingestion of aspirin or 
other non-steroidal anti-inflammatory drugs (NSAIDs)13,14. The pathogenesis of AIA is 
associated with alterations in arachidonate metabolic pathways15-17. Through the 
inhibition of the COX pathway, aspirin/NSAIDs divert AA metabolites to the LO 
pathway, resulting in a decrease in PGE2, anti-inflammatory PG, and an increase in the 
biosynthesis of cys-LTs15-17. In patients with AIA, an increased activity of LTC4S in 
bronchial mucosa has been observed, which is supported by a study that suggested a 
biallelic polymorphism in the promoter region of the LTC4S gene enhanced its 
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transcription18,19. Although several underlying genetic mechanisms of AIA have been 
proposed based on the identification of candidate genes other than LTC4S, to date, it 
appears that genetic influences on AIA are subtle20-23. Nevertheless, LT-modifying drugs 
are effective in blocking the bronchoconstriction provoked by aspirin and are typically 
used in the treatment of AIA24. Therefore, aspirin/NSAIDs may shift the balance of the 
5-LO pathway to augment airway inflammation and obstruction by the over-production 
of cys-LTs, including LTC4. However, it remains unclear in humans how cys-LTs are 
involved in the pathogenesis of AIA. Since LTC4S is the critical terminal enzyme for 
cys-LT biosynthesis in the 5-LO/LTC4S pathway, we generated LTC4S (Ltc4s) gene 
transgenic (LTC4S-Tg) mice to examine the functions of this synthase in vivo. In this 
study, we have clearly demonstrated for the first time that a shift in the balance towards 
the 5-LO pathway contributes to the pathogenesis of AIA in the presence of excess 
amounts of LTC4S.  
 
RESULTS 
OVA antigen-induced AHR in LTC4S-Tg and WT mice 
To investigate a role of LTC4S on the development of antigen-dependent asthma, the 
airway hyper-reactivity (AHR) to inhaled methacholine in LTC4S-Tg and WT mice 24 h 
(day 13) and 48 h (day 14) after immunization with OVA/alum was first measured (Fig. 
1). On day 13, increases in AHR were observed in both LTC4S-Tg and WT mice 
compared to the saline inhalation controls. The AHR was clearly augmented in the Tg 
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mice (Penh = 7.8 ± 0.5) than the WT mice (Penh = 4.0 ± 0.5) immunized with OVA; 
however, by day 14, the Penh value of Tg mice had reduced to a level similar to WT. At 
both measurement time points, the OVA-immunized LTC4S-Tg and WT mice displayed 
higher Penh values than the saline-immunized controls. 
Cell number of subpopulations in BALF after OVA challenge 
To analyze allergic inflammation in airways by OVA challenge, we determined the cell 
number and types present in the subpopulations in BALF obtained from the Tg and WT 
mice (Fig. 2a). Twenty-four hours after the OVA challenge, the total cell number in 
BALF was greater in Tg (8.1 ± 0.9 x 104) than in WT mice (4.9 ± 0.8 x 104). 
Significantly, the cell numbers of lymphocytes and eosinophils in the Tg mice were 
approximately 2- and 3-fold greater, respectively, than those in WT mice. The 
population distribution of other cell types was similar between both types of mice. 
However, 48 h after the OVA challenge, only the number of lymphocytes in the Tg mice 
(0.6 ± 0.2 x 104) was significantly higher than that in WT mice (0.3 ± 0.1 x 104). The 
total cell number in both groups of mice has decreased compared with those 24 h after 
the OVA challenge, although the cell number in the Tg mice (0.26 ± 0.02 x 105) 
remained greater than that in WT mice (0.21 ± 0.01 x 105). 
Antigen-induced Th2 cytokine production in airways 
Since an enhancement of lympocytosis and eosinophilia was observed in the Tg mice, 
we next analyzed Th2 cytokine production in the BALF samples 48 h after OVA 
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challenge (Fig. 2b). Although no differences between the Tg and WT mice were 
observed, the production of Th2 cytokines (IL-4, -5, -13) in Tg mice was greater than 
that in WT mice. The level of IFN-γ production was similar between both groups of 
mice. These results indicated that LTC4 was involved in the enhancement of Th2 
responses. 
LTC4 secretion by different cell types 
To investigate LTC4 secretion in culture supernatants by neutrophils, eosinophils, T cells, 
and macrophages from BALF, in addition to mast cells from spleens, each cell type was 
isolated 48 h after OVA challenge. After the isolated cells were seeded in culture dishes, 
they were stimulated with PMA and ionomycin for 1 h and the levels of LTC4 were 
quantified (Fig. 3). The amounts of LTC4 secreted by mast cells, eosinophils, and 
macrophages from Tg and WT were 1.12 ± 0.31 vs 0.11 ± 0.15 ng/ml, 0.42 ± 0.12 vs 
0.02 ± 0.03 ng/ml, and 0.11 ± 0.02 vs 0.02 ±0.01 ng/ml, respectively. In contrast, no 
LTC4 secretion by neutrophils and T cells was observed in either Tg or WT mice. In 
addition, LTC4 secretion was not detected in the culture supernatants of any cell types 
from both groups of mice without OVA challenge (data not shown).  
Effects of sulpyrine on LTC4 secretion from BAL cells  
We also examined the effects of sulpyrine on LTC4 secretion in culture supernatants by 
the total BAL cells isolated from Tg and WT mice 48 h after OVA challenge (Fig. 4). 
When cells were incubated with sulpyrine alone, a small amount of LTC4 was only 
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produced by BAL cells from LTC4S-Tg mice. In contrast, BAL cells stimulated with 
PMA and ionomycin produced much higher levels of LTC4, which was secreted by Tg 
cells (4.5 ± 0.6 ng/ml) at significantly greater quantities than those by WT cells (0.2 ± 
0.1 ng/ml). Furthermore, sulpyrine significantly augmented the secretion of LTC4 by 
PMA- and ionomycin-stimulated Tg cells (9.1 ± 1.0 ng/ml), but not WT cells (0.3 ± 0.2 
ng/ml). 
Effect of sulpyrine on airway response and secretion of chemical mediators in 
BALF 
To investigate the effect of COX pathway inhibition on the development of AIA, we 
measured airway resistance in Tg and WT mice immediately after inhalation of 
sulpyrine 48 h post-OVA challenge (Fig. 5a). Airway resistance in Tg and WT mice 
without OVA challenge (control) was unchanged by exposure to sulpyrine, whereas only 
OVA-challenged Tg mice demonstrated a significant increase in airway resistance, from 
0.52 ± 0.01 to 1.21 ± 0.22 (Penh values), by sulpyrine treatment at a concentration of 50 
mg/ml. Subsequently, we analyzed the secretion of LTC4 and several other chemical 
mediators, such as LTB4, LTC4, PGD2, PGE2, and histamine in BALF obtained from Tg 
and WT mice immediately after the last inhalation of sulpyrine (Fig. 5b). Tg and WT 
mice showed increases in PGD2 and PGE2 after challenge with OVA, which diminished 
or decreased significantly when mice were pre-treated with sulpyrine or not challenged 
with OVA. LTB4 was not detected in Tg and WT mice after provocation with sulpyrine 
or OVA, whereas sulpyrine induced LTB4 secretion in both Tg (125.4 ± 25.3 pg/ml) and 
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WT (40.4 ± 20.3 pg/ml) mice post-OVA challenge. LTC4 secretion was detected in WT 
mice (8.5 ± 2.3 pg/ml) only when they were administrated with sulpyrine after OVA 
provocation. In contrast, Tg mice demonstrated OVA-induced LTC4 secretion (8.4 ± 1.3 
pg/ml), which was further augmented by three-fold (27.5 ± 3.3 pg/ml) after the 
administration of sulpyrine, although LTC4 was not detected by sulpyrine treatment 
alone. The levels of LTB4 and LTC4 after sulpyrine administration in Tg mice were both 
3-fold higher than those in WT mice. We also observed an increase in histamine in Tg, 
but not WT, mice after challenge with OVA; however, sulpyrine had no effect on the 
histamine secretion in Tg mice.  
Effect of antagonist to the cys-LT1 receptor on sulpyrine-induced airway response 
To investigate the role of cys-LTs in AIA, we examined the effects of Pranlukast hydrate, 
an antagonist of the cys-LT1 receptor, on the sulpyrine-induced airway response in Tg 
and WT mice 48 h post-OVA challenge (Fig. 6). Although exposure to Pranlukast 
hydrate had no effect on airway resistance in WT mice regardless of the administration 
of sulpyrine, the AIA response was ameliorated in Tg mice, as shown by the reduction 
of airway resistance from 1.21 ± 0.22 to 0.62 ± 0.18 (Penh values).  
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DISCUSSION 
We demonstrated that in LTC4S-Tg mice, mast cells, eosinophils, and macrophages, but 
not neutrophils or T cells, produced excess amounts of LTC4 in immunized mice after 
antigen exposure, albeit under control of the CMV enhancer/chicken ß-actin promoter in 
the transgenic vector pCAGGS. Although the former three cell-types are known to 
synthesize cys-LTCs, including LTC425, the overexpression of LTC4 in LTC4S-Tg mice 
make them a useful model for the study of AIA. However, these Tg cells did not secrete 
LTC4 in the immunized Tg mice without antigen-challenge (data not shown), which 
indicates that LTC4 secretion requires not only sufficient levels of LTC4S, but also 
activation of a certain cell-specific pathway for its biosynthesis and subsequent export. 
Although we did not investigate LTC4 production by pulmonary endothelial cells, which 
are also a source of LTC4, these cells in Tg mice likely produce a large amount of 
cys-LTs26,27. LTC4 functions to accelerate development of the Th2 response and it has 
been suggested that dendritic cell/T cell interaction is modulated bifunctionally by 
cys-LTs, including LTC428-32. In addition, the intracrine cys-LT receptor plays a role in 
the Th2 response by mediating the signaling of eosinophil vesicular transport–mediated 
IL-4 secretion33. Here, we observed that Th2-type airway inflammation, which was 
characterized by eosinophilia, profound Th2 cytokine production, and increased AHR, 
was augmented in immunized LTC4S-Tg mice 24 h after antigen exposure. Although the 
detailed mechanism is unclear, it is known that Th2-type cytokines, such as IL-4 and 
IL-5, potentiate LTC4 synthesis by basophils, eosinophils, and mast cells34-36. 
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Thus, in the Tg mice, the high levels of LTC4 might serve to accelerate Th2 cytokine 
production, which in turn augments the biosynthesis and secretion of LTC4 by 
expression of the endogenous and/or exogenous LTC4S gene after immunization and 
challenge with antigen. Th2-type cytokines stimulate LTC4 synthesis, LTC4 might serve 
to accelerate Th2 cytokine production, and Th2 cytokines then augment the biosynthesis 
and secretion of LTC4. 
As most patients with AIA are non-atopic, in terms of antigen-dependent 
inflammation for the development of AIA, our murine model which is associated with 
antigen-dependent inflammation appears inappropriate for the examination of the 
development of AIA. However, chronic and persistent inflammation with increased 
numbers of mast cells and eosinophils have been observed in the bronchial mucosa of 
AIA patients with concomitant increases in nasal and oral exhaled IL-437-40. In addition, 
the bronchial mucosa of patients with AIA also exhibits elevated expression and 
enhanced local production of IL-541, which is the key regulator of eosinophil maturation 
and function. Therefore, the murine AIA model developed here is suitable for analyzing 
AIA with respected to eosinophilic inflammation associated with increased Th2 
cytokine production, regardless of its induction mechanism. The enhancement of LTC4 
secretion in the Tg mice was also demonstrated upon treatment with sulpyrine, which 
was further induced in airways (in vivo) by pre-challenge with antigen and in BAL cells 
(ex vivo) by stimulation with PMA/ionomycin. These results indicate that LTC4 
biosynthesis in activated cells is basically dependent on the level of LTC4S, which 
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might be amplified by allergic inflammatory factors, such as Th2 cytokines, and a 
sulpyrine-induced balance shift towards the 5-LO pathway in the AA metabolic cascade. 
The occurrence of such a balance shift was supported by findings that the synthesis of 
PGD2 and PGE2 was down-regulated in vivo after the treatment with sulpyrine. 
Decreased PGE2 levels are also typically observed in patients with AIA, suggesting that 
this anti-inflammatory PG may be involved in the pathogenesis of AIA. In contrast, 
there is relatively little evidence for the role of PGD2 in this disorder; however, Higashi 
et al have reported that the level of PGD2 increases in patients with AIA as compared to 
patients with aspirin-tolerant asthma (ATA), although other studies have not identified 
differences in PGD2 between AIA and ATA patients42. The decrease in PGD2 levels 
observed in this study may reflect the pharmacological action of sulpyrine on the AA 
metabolic pathway, which is independent of the actual pathogenesis of human AIA, in 
which the role of PGD2 remains uncertain. Nevertheless, the results presented here 
suggest that the action of LTC4 on airway obstruction is robust in the AIA model even 
though PGD2, which is potent bronco-constrictor, was down-regulated. Interestingly, in 
addition to LTC4, the amplified secretion of LTs was also demonstrated for LTB4 
synthesis in mice, particularly the LTC4S-Tg mice. Recently, it has been reported that 
LTB4 secretion is also increased in patients with AIA43. Although the detailed 
mechanisms in patients with AIA and the Tg mice have yet to be clarified, we speculate 
that the induction of LTA4 hydrolase by IL-4 and IL-13 may augment the secretion of 
LTB444.  
Notably, the AIA response in the Tg mice was observed by sulpyrine inhalation 48 h 
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after antigen exposure when it was confirmed prior to the sulpyrine treatment that AHR 
and cell population distribution, including eosinophils, in Tg mice had reduced to the 
identical or similar level to those in WT mice. Therefore, the AIA response that 
developed in the Tg mice might not be related to the preceding OVA-induced airway 
response, although LTC4-producing cells require priming with specific factors, such as 
Th2 cytokines. Taking into consideration the emergence of an AIA airway response that 
is distinct from the antigen-induced response, the pathogenesis of the AIA mouse model 
appears to mimic that of human AIA, which represents a type of non-allergic asthma.In 
LTC4S-Tg mice, the sulpyrine-induced airway response was completely abolished by an 
antagonist to the cys-LT1 receptor. Thus, this result supports our speculation that LTC4 
is a major player in AIA, and clearly demonstrates that the observed balance shift 
towards the 5-LO pathway in metabolism of AA contributes to the pathogenesis of AIA. 
However, as LTC4 was also secreted in vivo by WT mice following administration of 
sulpyrine after antigen exposure, although in lower amounts than that found in Tg mice, 
it appears that the level of LTC4 must exceed a certain threshold level for the 
development of AIA. This speculation is supported by a report that LTs were found in 
urine in high concentrations at baseline, but after the ingestion of aspirin, large amounts 
of LTs were formed and detectable in the urine45,46. Furthermore, it has been reported 
that the number of activated eosinophils that are immunoreactive for LTC4S are elevated 
in the bronchial mucosa of AIA patient compared to that from ATA patients47. In 
addition, the overexpression of LTC4S is strongly correlated with elevated levels of 
cys-LTs in BALF from AIA patients in a stable state and with AHR to inhaled aspirin47.  
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Taken together, these reports suggest that the increase of LTC4S in inflammatory cells of 
human airways in a stable state may be a hallmark of AIA.  
In conclusion, by generating and examining LTC4S-Tg mice, we demonstrated for the 
first time that AIA can be induced in the presence of elevated levels of cyst-LTs owing 
to persistent airway inflammation characterized by eosinophilic inflammation associated 
with an environment enriched in Th2 cytokines, independently of the presence of 
antigen-induced airway obstruction. Our study strongly suggests that cys-LTs play a 
major role in the pathogenesis of AIA in patients with chronic asthma. 
 
METHODS 
Reagents and antibodies. Magnetic microbeads labeled with anti-CD90 (Thy1.2), 
-CD45R (B220), -CD11b, -CD11c, or -PE antibodies (abs) were purchased from 
Miltenyi Biotec (Gladbach, Germany). PE-conjugated anti-CD3ε chain, 
APC-conjugated anti- CD11b, APC- and PE-conjugated anti-Gr-1(Ly-6G), and 
APC-conjugated anti- c-kit (CD117) abs were purchased from BD Biosciences 
Pharmingen (San Diego, CA, USA). PE-conjugated anti-Fc ε RIα was purchased from 
eBioscience (San Diego, CA, USA). PE-conjugated anti-chemokine receptor (CCR)3 
was purchased from R&D Systems (Minneapolis, MN, USA). 
Generation of LTC4S-Tg mice. To generate transgenic mice containing the Ltc4s gene, 
we amplified murine cDNA encoding the full-length LTC4S protein and placed it under 
the control of a CMV enhancer/chicken ß-actin promoter in the transgenic vector 
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pCAGGS48, which has been shown to facilitate widespread transgene expression in mice. 
Detailed methodology is described in the Supplementary Methods. All mice were 
maintained under specific pathogen-free conditions in the animal center at Dokkyo 
University School of Medicine. This study was approved by the Ethics Committee for 
Animal. 
Sensitization and antigen challenge, sulpyrine administration, and treatment with 
mouse cys-LTs receptor antagonist. An outline of the protocols used in this study is 
shown in the Supplementary Fig. 1. To investigate the roles of LTC4S in the 
development of AIA, we first established an antigen-dependent murine model of asthma. 
Briefly, LTC4S-Tg and wild-type (WT) mice were intraperitoneally injected on days 0 
and 5 with ovalbumin (OVA ) (Sigma-Aldrich) (8 μg/mouse) adsorbed in aluminum 
hydroxide (alum) (Wako Pure Chemical Industries) for sensitization, or aluminum 
hydroxide alone as a control. To induce airway inflammation, the sensitized and control 
mice were challenged with aerosolized 1% OVA or saline, respectively, for 60 min on 
day 12. On day 13, the mice were analyzed for airway hyper-reactivity (AHR). 
Subsequently, on day 14, a second analysis for AHR was performed, which was 
followed by bronchial-alveolar lavage (BAL) and splenectomy for cellular analysis. For 
the establishment of the AIA model, 48 h after the OVA challenge, mice were 
provocated with aerosol inhalation of sulpyrine (1, 10, or 50 mg/ml) or saline for 30 min. 
After 2 h, airway resistance was measured, and then BAL was performed. In addition, to 
access the effect of a LTC4 receptor antagonist on the development of AIA, Pranlukast 
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hydrate (ONO Pharmaceutical Co., Osaka, Japan) or lactose (Sigma-Aldrich, St.Louis, 
MO, USA) as the control were dissolved in dimethylsulfoxide and given to mice by 
intragastric administration (25 mg/kg body weight)1 h prior to sulpyrine (50 mg/ml) 
inhalation.  
Measurement of airway resistance. To estimate AHR to inhaled methacholine or AIA, 
airway resistance in conscious, spontaneously breathing mice was measured by 
barometric whole-body plethysmography (Buxco Electronics) as described previously 
49,50. Briefly, saline or increasing concentrations of methacholine (6–24 mg/ml) or 
sulpyrine (1–50 mg/ml) were aerosolized through an inlet of the main chamber of the 
plethysmograph. Methacholine or sulpyrine was provocated for 3 or 30 min, 
respectively, and readings were recorded and averaged 3 min after each challenge. 
Airway resistance was expressed as enhanced pause (Penh) values for each tested 
concentration.  
Bronchial-alveolar lavage. BAL was performed immediately after the last aerosol 
provocation with OVA, methacholine or sulpyrine (Supplementary Methods).  
Cells preparation. Macrophages, T cells, neutrophils and eosinophils, or mast cells 
were obtained from BAL cells, or splenocytes, respectively (Supplementary Methods).  
Cell culture for LTC4 measurement. For the measurement of LTC4 production, the 
isolated neutrophils, eosinophils, T cells, macrophages, and mast cells (2 x 105/ml) were 
cultured in RPMI 1640/10% FCS in the presence or absence of both phorbol myristate 
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acetate (PMA) (25 ng/ml) (Sigma, St. Louis, Mo, USA) and ionomycin (1 µg/ml) 
(Sigma, St. Louis, Mo, USA). After an 1-h incubation, the amount of LTC4 in the 
culture supernatant was measured using an enzyme-immunoassay (EIA). To examine 
effects of sulpyrine on LTC4 secretion, the BAL cells (2 x 105/well) were treated with 
sulpyrine (1 µg/ml) for 1 h prior to the activation by PMA/ionomycin in RPMI 
1640/10% FCS medium in 96-well plates, which were incubated at 37 °C in a 5% CO2 
environment.  
Measurement of chemical mediator and cytokines. Concentrations of LTB4, LTC4, 
prostaglandin (PG)D2 (Cayman, Ann Arbor, MI, USA), PGE2 (Oxford Biomedical 
Research, Oxford, MI, USA), histamine (SPI Bio, Montigny le Bretonneux, France) in 
BALF or culture supernatants were assessed by enzyme immune assay (EIA) 
(Supplementary Methods). 
Statistical analysis. Data are expressed as the mean ± SD. The statistical significance of 
differences between groups was examined by one-way analysis of variance with 
Bonferroni’s test. P values of less than 0.05 were considered to indicate statistical 
significance.  
ACKNOWLEDGMENTS 
We thank Mrs. Kazumi Okazaki, Mrs. Takako Takako, Miss. Yuko Kotemori, Mr 
Takashi Namatame, Mr. Masahide Oyama, and Mr. Hiromichi Kaneko for skillful 
technical assistance. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
17 
 
AUTHOR CONTRIBUTIONS 
H.H. performed initial experiments and participated in the writing of the paper; Y.F. and 
K.H. designed the study and analyzed the data; M.A., T.T., and T.F. designed the study 
and wrote paper. 
COMPETING FINANCIAL INTEREST 
The authors declare that they have no competing financial interests.  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
18 
 
REFERNCES 
1. Cowburn, A.S., Holgate, S.T. & Sampson, A.P. IL-5 increases expression of 
5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in 
human blood eosinophils. J. Immunol. 163, 456-465 (1999). 
2. Sjostrom, M. et al. Human mast cells express two leukotriene C4 synthase 
isoenzymes and the CysLT1 receptor. Biochim. Biophys. Acta. 1583, 53–62 (2002). 
3. Voelkel, N.F. et al. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces 
pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J. Clin. 
Invest. 97, 2491–2498 (1996). 
4. Ford-Hutchinson, A.W., Gresser, M & Young, R.N. 5-Lipoxygenase. Annu. Rev. 
Biochem. 63, 383–417 (1994). 
5. Martinez, M.D. et al. Structural basis for synthesis of inflammatory mediators by 
human leukotriene C4 synthase. Nature. 448, 613-616 (2007).  
6. Maekawa, A., Kanaoka, Y., Xing, W. & Austen, K.F. Functional recognition of a 
distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene.  
Proc. Natl. Acad. Sci. U S A. 105, 16695-17700 (2008).  
7. Lee, K.S. et al. Cysteinyl leukotriene upregulates IL-11 expression in allergic airway 
disease of mice. J. Allergy. Clin. Immunol. 119, 141-149 (2007).  
8. Holgate, S.T., Peters-Golden, M., Panettieri, R.A. & Henderson, W.R. Jr. Roles of 
cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. 
J. Allergy .Clin. Immunol. 111, S18-34; discussion S34-36 (2003). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
19 
 
9. Busse, W.W. Leukotrienes and inflammation. Am. J. Respir. Crit. Care. Med. 157, 
S210-213; discussion S247-248 (1998). 
10. Lee, K.S., Kim, S.R., Park, H.S., Jin, G.Y. & Lee, Y.C. Cysteinyl leukotriene 
receptor antagonist regulates vascular permeability by reducing vascular endothelial 
growth factor expression. J. Allergy. Clin. Immunol. 114, 1093-1099 (2004). 
11. Szczeklik, A. Mechanism of aspirin-induced asthma. Allergy. 52, 613-619 (1997). 
12. Dahlén, B. et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to 
conventional therapy in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care. Med. 
157, 1187-1194 (1998). 
13. Szczeklik, A. & Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis 
and management. J. Allergy. Clin. Immunol. 104, 5-13 (1999). 
14. Samter, M. & Beers, R.F.Jr. Intolerance to aspirin. Clinical studies and 
consideration of its pathogenesis. Ann. Intern. Med. 68, 975-983 (1968). 
15. Kumlin, M. et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane 
B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and 
histamine in asthmatics. Am. Rev. Respir. Dis. 146, 96-103 (1992). 
16. Ortolani, C. et al. Study of mediators of anaphylaxis in nasal wash fluids after 
aspirin and sodium metabisulfite nasal provocation in intolerant rhinitic patients. Ann. 
Allergy. 59, 106-112 (1987). 
17. Kowalski, M.L. et al. Nasal secretions in response to acetylsalicylic acid. J. Allergy. 
Clin. Immunol. 91, 580-598 (1993). 
18. Cowburn, A.S., Holgate, S.T. & Sampson, A.P. IL-5 increases expression of 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
20 
 
5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in 
human blood eosinophils. J. Immunol. 163, 456-465 (1999). 
19. Sanak, M., Pierzchalska, M., Bazan-Socha, S. & Szczeklik, A. Enhanced expression 
of the leukotriene C(4) synthase due to overactive transcription of an allelic variant 
associated with aspirin-intolerant asthma. Am. J. Respir. Cell. Mol. Biol. 23, 290-296 
(2000). 
20. Jinnai, N. et al. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene 
confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum. Mol. 
Genet. 13, 3203-3017 (2004).  
21. Sakagami, T. et al. ADAM33 polymorphisms are associated with aspirin-intolerant 
asthma in the Japanese population. J. Hum. Genet. 52, 66-72. (2007). 
22. Palikhe, N.S. et al. Association of three sets of high-affinity IgE receptor 
(FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respir. Med. 102, 
1132-1139 (2008).  
23. Palikhe, N.S. et al. IL-13 Gene polymorphisms are associated with rhinosinusitis 
and eosinophilic inflammation in aspirin intolerant asthma. Allergy. Asthma. 
Immunol .Res. 2, 134-140 (2010).  
24. Hamad, A.M., Sutcliffe, A.M. & Knox, A.J. Aspirin-induced asthma: clinical 
aspects, pathogenesis and management. Drugs. 64, 2417-2432 (2004). 
25. Marc, Peters-Golden, M.D. & William, R.H.Jr. Mechanisms of Disease, 
Leukotrienes. N. Engl. J. Med. 357, 1841-1854 (2007). 
26. Folco, G. & Murphy, R.C. Eicosanoid transcellular biosynthesis: from cell-cell 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
21 
 
interactions to in vivo tissue responses. Pharmacol. Rev. 58, 375-388 (2006). 
27. Feinmark, S.J. & Cannon, P.J. Endothelial cell leukotriene C4 synthesis results from 
intercellular transfer of leukotriene A4 synthesized by polymorphonuclear leukocytes. J. 
Biol. Chem. 261, 16466-16472 (1986). 
28. Machida, I. et al. Cysteinyl leukotrienes regulate dendritic cell functions in a murine 
model of asthma. J. Immunol. 172, 1833-1838 (2004). 
29. Daniel, C. et al. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary 
inflammation. J. Immunol. 176, 4440-4448 (2006). 
30. Robbiani, D.F. et al. The leukotriene C4 transporter MRP1 regulates CCL19 
(MIP-3b, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell. 103, 
757-768 (2000). 
31. Okunishi, K., Dohi, M., Nakagome, K.,Tanaka, R. & Yamamoto, K. A novel role of 
cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced 
immune responses in the lung. J. Immunol. 173, 6393-6402 (2004). 
32. Parameswaran, K. et al. Role for cysteinyl leukotrienes in allergen induced change 
in circulating dendritic cell number in asthma. J. Allergy. Clin. Immunol. 114, 73-79 
(2004). 
33. Bandeira-Melo, C., Woods, L.J., Phoofolo, M. & Weller, P.F. Intracrine cysteinyl 
leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated 
interleukin-4 secretion. J. Exp. Med. 196, 841-850, 2002.  
34. Muñoz, N.M., van Seventer, G.A., Semnani, R.T. & Leff, A.R. Augmentation of 
LTC4 synthesis in human eosinophils caused by CD3-stimulated Th2-like cells in vitro 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
22 
 
Am. J. Physiol. Lung. Cell. Mol. Physiol. 278, L1172-L1179 (2000). 
35.Sarmiento, E.U., Espiritu B.R., Gleich, G.J. & Thomas, L.L. IL-3, IL-5, and 
granulocyte-macrophage colony-stimulating factor potentiate basophil mediator release 
stimulated by eosinophil granule major basic protein. J. Immunol. 155, 2211-2221 
(1995). 
36. Hsieh, F.H., Lam, B.K., Penrose, J.F., Austen, K.F. & Boyce, J.A. T helper cell type 
2 cytokines coordinately regulate immunoglobulin E–dependent cysteinyl leukotriene 
production by human cord blood–derived mast cells profound induction of leukotriene 
C4 synthase expression by interleukin 4. J. Exp. Med. 193, 123-134 (2001). 
37. Babu, K.S. & Salvi, S.S. Aspirin and Asthma. CHEST. 118, 1470-1476 (2000). 
38. Vaszar, L.T. & Stevenson, D.D. Aspirin-induced asthma. Clin. Rev. Allergy. Immunol. 
21, 71-87 (2001). 
39. Bochenek, G., Bánska, K., Szabó, Z., Nizankowska, E. & Szczeklik, A. Diagnosis, 
prevention and treatment of aspirin-induced asthma and rhinitis. Curr. Drug. Targets. 
Inflamm. Allergy. 1, 1-11(2002). 
40. Carpagnano, G.E. et al. Exhaled inflammatory markers in aspirin-induced asthma 
syndrome. Am. J. Rhinol. 21, 542-547 (2007). 
41. Sousa, A.R. et al. Expression of interleukin-5 and granulocyte-macrophage colony- 
stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am. 
J. Respir. Crit. Care. Med. 156, 1384-1389 (1997). 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
23 
 
42. Higashi, N. et al. Profile of eicosanoid generation in aspirin-intolerant asthma and 
anaphylaxis assessed by new biomarkers. J. Allergy. Clin. Immunol. 125, 1084-1091 
(2010).  
43. Mita, H., Higashi, N., Taniguchi, M., Higashi, A. & Akiyama, K. Increase in urinary 
leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after 
intravenous aspirin challenge. Clin. Exp. Allergy. 34, 1262-1269 (2004). 
44. Zaitsu, M. et al. New induction of leukotriene A4 hydrolase by interleukin-4 and 
interleukin-13 in human polymorphonuclear leukocytes. Blood. 96, 601-609 (2000). 
45. Szczeklik, A. Mechanism of aspirin-induced asthma. Allergy. 52, 613-619 (1997). 
46. Christie, P.E. et al. Urinary leukotriene E4 concentrations increase after aspirin 
challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143, 1025–1029 
(1991). 
47. Cowburn, A.S. et al. Overexpression of leukotriene C4 synthase in bronchial 
biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 101, 834-846 
(1998). 
48. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression 
transfectants with a novel eukaryotic vector. Gene. 108, 193–199 (1991). 
49. Honda, K. et al. Prostaglandin D2 reinforces Th2 type inflammatory responses of 
airways to low-dose antigen through bronchial expression of macrophage-derived 
chemokine. J. Exp. Med. 198, 533-543 (2003). 
50. Cheng, G. et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation 
and hyperreactivity in mouse asthma model. Am. J. Respir. Crit. Care. Med. 166, 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
75
1.
1 
: P
os
te
d 
10
 A
ug
 2
01
0
24 
 
409-416 (2002). 
 
 
 
 
 
 
 
 
Figure legends 
Figure 1 AHR to inhaled mathacholine in LTC4S-Tg and WT mice after an antigen 
challenge. The AHR in mice immunized with OVA/alum was estimated 24 h (day 13) 
and 48 h (day 14) after antigen (Tg, closed circle; WT, open circle) or saline as control 
(Tg, closed square; WT, open square) exposure. Airway resistance was expressed as 
enhanced pause (Penh) values for each concentration of methacholine (6, 12, and 24 
mg/ml) or saline (controls). Data are expressed as the mean ± SD for each group (n=7). 
*P<0.05, **P<0.01 as compared to immunized WT mice after antigen challenge.  
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Figure 2 Cell number, types and concentration of cytokines in BALF samples from 
LTC4S-Tg and WT mice after antigen challenge. (a) The number of cells were assessed 
24 and 48 h after antigen (OVA+) or saline (OVA-) (Tg, closed bar; WT, open bar) 
exposure. Data are expressed as the mean ± SD for each group (n=7). *P<0.05, 
**P<0.01 as compared to immunized WT mice after antigen challenge. MΦ, 
macrophages; Ly, lymphocytes; Neu, neutrophils; Eo, eosinophils. (b) The 
concentration of Th2 cytokines (IL-4, IL-5, IL-13) and Th1 cytokine (IFN-γ) in samples 
were measured 24 and 48 h after mice were immunized with either antigen (OVA+) or 
saline (OVA-) (Tg, closed bar; WT, open bar). The concentration of cytokines in the 
supernatants was determined by ELISA. Data are expressed as the mean ± SD for each 
group (n=7). *P<0.05 as compared to immunized WT mice after antigen challenge. ND, 
not detected. 
Figure 3 LTC4 secretion by inflammatory cells from mice after antigen challenge. 
Macrophages, T cells, neutrophils, and eosinophils were isolated from BALF, and mast 
cells were isolated from spleens of mice 48 h after antigen challenge. LTC4 in culture 
supernatants of each cell type was measured 1 h after stimulation with PMA and 
ionomycin. The concentration of LTC4 in the supernatants was quantified by EIA. Data 
are expressed as the mean ± SD for each group (n=10). *P<0.05 as compared to WT 
mice. MΦ, macrophages; Neu, neutrophils; Eo, eosinophils; MC, mast cells.  
Figure 4 Effects of sulpyrine on LTC4 secretion by BAL cells from mice 48 h after 
antigen challenge. LTC4 in the culture supernatants of total BAL cells from Tg (closed 
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bar) and WT (open bar) mice was measured after a 1-h stimulation with PMA and 
ionomycin in the presence or the absence of sulpyrine. Data are expressed as the mean ± 
SD for each group (n=8). *P<0.05 as compared to WT mice or Tg mice in the absence 
of sulpyrine.  
Figure 5 Effect of sulpyrine on airway response and secretion of chemical mediators in 
BALF. (a) Airway resistance in Tg and WT mice with or without OVA challenge 
(OVA+ or OVA-, respectively) was analyzed immediately after administration of 
sulpyrine (1, 10, or 50 mg/ml) or saline. Airway reactivity was expressed as enhanced 
pause (Penh) values for each concentration of sulpyrine, the saline controls, and 
baseline. Data are expressed as the mean ± SD for each group (n=6). *P<0.05 as 
compared to WT mice (OVA+). (b) Concentrations of LTB4, LTC4, PGD2, PGE2, and 
histamine in BAL fluid were quantified by EIA. BAL fluid was obtained immediately 
after inhalation of sulpyrine or saline in Tg (closed bar) and WT (open bar) mice 48 h 
after antigen (OVA+) or saline (OVA-) exposure. Data are expressed as the mean ± SD 
for each group (n=7). *P<0.05 as compared to immunized WT mice in the presence of 
sulpyrine, or immunized Tg mice in the absence of sulpyrine. 
Figure 6 Effect of antagonist to the cys-LT1 receptor on sulpyrine-induced airway 
responses.  Forty-eight hours after antigen challenge, Tg (closed bar) and WT (open 
bar) mice were orally administered Pranlukast hydrate (25 mg/kg body weight) or 
lactose (control), and 1 h later, were administered either sulpyrine (50 mg/ml) or saline 
using a nebulizer for 30 min. Airway resistance was measured immediately after the 
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final inhalation. Airway reactivity was expressed as enhanced pause (Penh) values for 
the dosage of Pranlukast hydrate or lactose with or without the administration of 
sulyprine. Data are expressed as the mean ± SD for each group (n=6). *P<0.05 as 
compared to LTC4S-Tg administered sulpyrine in the absence of Pranlukast hydrate. 
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